Skip to main content
Erschienen in: International Journal of Clinical Oncology 3/2022

27.11.2021 | Original Article

Predictive factors of survival of colorectal cancer patients after para-aortic lymph node metastasis

verfasst von: Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Shigenobu Emoto, Shinya Abe, Hirofumi Sonoda, Koji Murono, Junko Kishikawa, Yuzo Nagai, Yuichiro Yokoyama, Hiroyuki Anzai, Soichiro Ishihara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Para-aortic lymph node (PALN) metastasis is an ominous manifestation indicating a poor prognosis in colorectal cancer (CRC) patients; however, some treatments prolong survival. In this study, we investigated predictors of prolonged survival in CRC patients after PALN metastasis.

Methods

We examined 141 patients with CRC that metastasized to the PALNs from CRC with or without extra-PALN metastasis. Among clinicopathological parameters, factors associated with survival after PALN metastasis were identified by multivariate analyses using Cox’s proportional hazard models.

Results

The mean hemoglobin and albumin values at diagnosis were 12.3 g/dL and 3.7 g/dL, respectively. Rectal cancer was predominant (n = 81). Mutated RAS was detected in 43%. One hundred and four patients had differentiated adenocarcinoma. Patients underwent PALN dissection (n = 11), radiotherapy (n = 6), and systemic therapy (n = 120). Biologics were administered to 95 patients. The median survival time was 29.1 months. On multivariate analysis, independent factors associated with reduced survival after PALN metastasis were low albumin (hazard ratio [HR] 2.33 per −1 g/dL), mutated RAS (HR 2.55), other than differentiated adenocarcinoma (HR 2.75), rectal cancer (HR 3.38 against right-sided colon, and 3.48 against left-sided colon), the presence of extra-PALN metastasis (HR 6.56), and no use of biologics (HR 3.04).

Conclusions

This study revealed that hypoalbuminemia as well as RAS mutation, undifferentiated histology, rectal cancer, other site metastasis, and no use of biologics contribute to poor prognosis in CRC patients with PALN metastasis. Nutritional management may be important for improving survival of these patients.
Literatur
1.
Zurück zum Zitat van der Geest LG, Lam-Boer J, Koopman M et al (2015) Nationwide trends in incidence, treatment and survival of colorectal: cancer patients with synchronous metastases. Clin Exp Metastasis 32:457–465CrossRef van der Geest LG, Lam-Boer J, Koopman M et al (2015) Nationwide trends in incidence, treatment and survival of colorectal: cancer patients with synchronous metastases. Clin Exp Metastasis 32:457–465CrossRef
2.
Zurück zum Zitat van der Pool AE, Damhuis RA, Ijzermans JN et al (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14:56–61CrossRef van der Pool AE, Damhuis RA, Ijzermans JN et al (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14:56–61CrossRef
5.
Zurück zum Zitat Brierley JD, Gospodarowicz MK, Wittekind Ch (2016) TNM classification of malignant tumors, 8th edn. Wiley-Blackwell, Oxford Brierley JD, Gospodarowicz MK, Wittekind Ch (2016) TNM classification of malignant tumors, 8th edn. Wiley-Blackwell, Oxford
6.
Zurück zum Zitat Shibata D, Paty PB, Guillem JG et al (2002) Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum 45:795–801CrossRef Shibata D, Paty PB, Guillem JG et al (2002) Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum 45:795–801CrossRef
7.
Zurück zum Zitat Min BS, Kim NK, Kim NK et al (2008) Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol 97:136–140CrossRef Min BS, Kim NK, Kim NK et al (2008) Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol 97:136–140CrossRef
8.
Zurück zum Zitat Choi PW, Kim HC, Kim AY et al (2010) Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph node metastasis below the level of renal vessels. J Surg Oncol 101:66–71CrossRef Choi PW, Kim HC, Kim AY et al (2010) Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph node metastasis below the level of renal vessels. J Surg Oncol 101:66–71CrossRef
9.
Zurück zum Zitat Bae SU, Hur H, Min BS et al (2018) Which patients with isolated para-aortic lymph node metastasis will truly benefit from extended lymph node dissection for colon cancer? Cancer Res Treat 50:712–719CrossRef Bae SU, Hur H, Min BS et al (2018) Which patients with isolated para-aortic lymph node metastasis will truly benefit from extended lymph node dissection for colon cancer? Cancer Res Treat 50:712–719CrossRef
10.
Zurück zum Zitat Sakamoto J, Ozawa H, Nakanishi H et al (2020) Oncologic outcomes after resection of para-aortic lymph node metastasis in left-sided colon and rectal cancer. PLoS ONE 15:e0241815CrossRef Sakamoto J, Ozawa H, Nakanishi H et al (2020) Oncologic outcomes after resection of para-aortic lymph node metastasis in left-sided colon and rectal cancer. PLoS ONE 15:e0241815CrossRef
11.
Zurück zum Zitat Nakai N, Yamaguchi T, Kinugasa Y et al (2017) Long-term outcomes after resection of para-aortic lymph node metastasis from left-sided colon and rectal cancer. Int J Colorectal Dis 32:999–1007CrossRef Nakai N, Yamaguchi T, Kinugasa Y et al (2017) Long-term outcomes after resection of para-aortic lymph node metastasis from left-sided colon and rectal cancer. Int J Colorectal Dis 32:999–1007CrossRef
12.
Zurück zum Zitat Yamada K, Tsukamoto S, Ochiai H et al (2019) Improving selection for resection of synchronous para-aortic lymph node metastases in colorectal cancer. Dig Surg 36:369–375CrossRef Yamada K, Tsukamoto S, Ochiai H et al (2019) Improving selection for resection of synchronous para-aortic lymph node metastases in colorectal cancer. Dig Surg 36:369–375CrossRef
13.
Zurück zum Zitat Arimoto A, Uehara K, Kato T et al (2015) Clinical significance of para-aortic lymph node dissection for advanced or metastatic colorectal cancer in the current era of modern chemotherapy. Dig Surg 32:439–444CrossRef Arimoto A, Uehara K, Kato T et al (2015) Clinical significance of para-aortic lymph node dissection for advanced or metastatic colorectal cancer in the current era of modern chemotherapy. Dig Surg 32:439–444CrossRef
14.
Zurück zum Zitat Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRef Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRef
15.
Zurück zum Zitat Yoshino T, Arnold D, Taniguchi H et al (2018) Pan–Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44–70CrossRef Yoshino T, Arnold D, Taniguchi H et al (2018) Pan–Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44–70CrossRef
16.
Zurück zum Zitat Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1–42CrossRef Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1–42CrossRef
17.
Zurück zum Zitat Yeo SG, Kim DY, Kim TH et al (2010) Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer. Radiother Oncol 97:307–311CrossRef Yeo SG, Kim DY, Kim TH et al (2010) Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer. Radiother Oncol 97:307–311CrossRef
18.
Zurück zum Zitat Lee J, Chang JS, Lim JS et al (2015) Incorporation of radiotherapy in the multidisciplinary treatment of isolated retroperitoneal lymph node recurrence from colorectal cancer. Ann Surg Oncol 22:1520–1526CrossRef Lee J, Chang JS, Lim JS et al (2015) Incorporation of radiotherapy in the multidisciplinary treatment of isolated retroperitoneal lymph node recurrence from colorectal cancer. Ann Surg Oncol 22:1520–1526CrossRef
19.
Zurück zum Zitat Shu P, Ouyang G, Wang F et al (2020) The role of radiotherapy in the treatment of retroperitoneal lymph node metastases from colorectal cancer. Cancer Manag Res 12:8913–8921CrossRef Shu P, Ouyang G, Wang F et al (2020) The role of radiotherapy in the treatment of retroperitoneal lymph node metastases from colorectal cancer. Cancer Manag Res 12:8913–8921CrossRef
20.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef
21.
Zurück zum Zitat Hohenberger W, Weber K, Matzel K et al (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation–technical notes and outcome. Colorectal Dis 11:354–364 (discussion 364–365)CrossRef Hohenberger W, Weber K, Matzel K et al (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation–technical notes and outcome. Colorectal Dis 11:354–364 (discussion 364–365)CrossRef
22.
Zurück zum Zitat Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616CrossRef Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616CrossRef
23.
Zurück zum Zitat Takiyama H, Kawai K, Ishihara S et al (2018) Different impacts of preoperative radiotherapy and chemoradiotherapy on oncological outcomes in patients with stages II and III lower rectal cancer: a propensity score analysis. Dig Surg 35:212–219CrossRef Takiyama H, Kawai K, Ishihara S et al (2018) Different impacts of preoperative radiotherapy and chemoradiotherapy on oncological outcomes in patients with stages II and III lower rectal cancer: a propensity score analysis. Dig Surg 35:212–219CrossRef
24.
Zurück zum Zitat Nozawa H, Ishihara S, Kawai K et al (2018) Conversion to resection in patients receiving systemic chemotherapy for unresectable and/or metastatic colorectal cancer-predictive factors and prognosis. Clin Colorectal Cancer 17:e91–e97CrossRef Nozawa H, Ishihara S, Kawai K et al (2018) Conversion to resection in patients receiving systemic chemotherapy for unresectable and/or metastatic colorectal cancer-predictive factors and prognosis. Clin Colorectal Cancer 17:e91–e97CrossRef
25.
Zurück zum Zitat Singh H, Longo DL, Chabner BA (2015) Improving prospects for targeting RAS. J Clin Oncol 33:3650–3659CrossRef Singh H, Longo DL, Chabner BA (2015) Improving prospects for targeting RAS. J Clin Oncol 33:3650–3659CrossRef
26.
Zurück zum Zitat Shin SM, Choi DK, Jung K et al (2017) Antibody targeting intracellular oncogenic RAS mutants exerts anti-tumour effects after systemic administration. Nat Commun 8:15090CrossRef Shin SM, Choi DK, Jung K et al (2017) Antibody targeting intracellular oncogenic RAS mutants exerts anti-tumour effects after systemic administration. Nat Commun 8:15090CrossRef
27.
Zurück zum Zitat Vauthey JN, Zimmitti G, Kopetz SE et al (2013) RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258:619–626CrossRef Vauthey JN, Zimmitti G, Kopetz SE et al (2013) RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258:619–626CrossRef
28.
Zurück zum Zitat Amikura K, Akagi K, Ogura T et al (2018) The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: the results from a genetic analysis of all-RAS. J Surg Oncol 117:745–755CrossRef Amikura K, Akagi K, Ogura T et al (2018) The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: the results from a genetic analysis of all-RAS. J Surg Oncol 117:745–755CrossRef
29.
Zurück zum Zitat Ren J, Li G, Ge J et al (2012) Is K-RAS gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 55:913–923CrossRef Ren J, Li G, Ge J et al (2012) Is K-RAS gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 55:913–923CrossRef
30.
Zurück zum Zitat Rui YY, Zhang D, Zhou ZG et al (2013) Can K-RAS gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PLoS ONE 8:e77901CrossRef Rui YY, Zhang D, Zhou ZG et al (2013) Can K-RAS gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PLoS ONE 8:e77901CrossRef
31.
Zurück zum Zitat Stillwell AP, Ho YH, Veitch C (2011) Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg 35:684–692CrossRef Stillwell AP, Ho YH, Veitch C (2011) Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg 35:684–692CrossRef
33.
Zurück zum Zitat Sjoquist KM, Renfro LA, Simes RJ et al (2018) Personalizing survival predictions in advanced colorectal cancer: the ARCAD Nomogram Project. J Natl Cancer Inst 110:638–648CrossRef Sjoquist KM, Renfro LA, Simes RJ et al (2018) Personalizing survival predictions in advanced colorectal cancer: the ARCAD Nomogram Project. J Natl Cancer Inst 110:638–648CrossRef
34.
Zurück zum Zitat Okada S, Yamazaki S, Kaiga T et al (2017) Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy. World J Surg Oncol 15:162CrossRef Okada S, Yamazaki S, Kaiga T et al (2017) Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy. World J Surg Oncol 15:162CrossRef
Metadaten
Titel
Predictive factors of survival of colorectal cancer patients after para-aortic lymph node metastasis
verfasst von
Hiroaki Nozawa
Kazushige Kawai
Kazuhito Sasaki
Shigenobu Emoto
Shinya Abe
Hirofumi Sonoda
Koji Murono
Junko Kishikawa
Yuzo Nagai
Yuichiro Yokoyama
Hiroyuki Anzai
Soichiro Ishihara
Publikationsdatum
27.11.2021
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2022
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-021-02095-4

Weitere Artikel der Ausgabe 3/2022

International Journal of Clinical Oncology 3/2022 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.